ArtusLabs | GenomeWeb

ArtusLabs

PE's most recent catch, the latest in a string of recent informatics purchases, markets the Nexxis electronic laboratory notebook; Nexxis iLAB, a laboratory automation platform; and LimsLink, a lab integration software platform.

"We see informatics as a real opportunity," PerkinElmer CEO Robert Friel said during a conference call to discuss the company's Q1 results. Now the company is mulling how to integrate the three new software firms it acquired over the past two months.

PerkinElmer has completed its acquisition of ArtusLabs and has agreed to purchase CambridgeSoft. The combined purchase price for the two software firms totals $220 million.

The two deals for $220 million in aggregate will expand PerkinElmer's informatics and software offerings and enable customers to access and share enterprise-wide data "for faster, more informed scientific decisions."

News Scan

Premium

DiscoveryBioMed, ArtusLabs, Heptares Therapeutics, Gentronix, GlaxoSmithKline, BioFocus DPI, Eli Lilly, Millipore, Epitome, ChanTest, Applied Cell Sciences, BioTime, Embryome Sciences, Reproductive Genetics Institute of Chicago, Arizona State University Biodesign Institute, VisionGate

The partnership will use ArtusLabs' web-based platform Ensemble for Life Science as the data-management platform.

In Nature this week: genome-wide transcriptome analysis of brain samples from people with autism spectrum disorder, flounder genome, and more.

Researchers used T-cell transfer therapy to target mutation KRAS, according to the New York Times.

The US Senate has passed the 21st Century Cures Act, which would provide a funding boost at NIH while overhauling FDA policies.

Bloomberg reports that President-elect Donald Trump is considering Jim O'Neill for Food and Drug Administration commissioner.